Roadmap for implementation of quality by design (QbD) for biotechnology products
Tóm tắt
Từ khóa
Tài liệu tham khảo
Woodcock, J. (2005) Pharmaceutical quality in the 21st century – an integrated systems approach. In AAPS Workshop on Pharmaceutical Quality Assessment – A Science and Risk-Based CMC Approach in the 21st Century
Department of Health and Human Services, Food and Drug Administration (2004) PAT Guidance for Industry – A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance
International Conference of Harmonisation (2008) ICH Harmonised Tripartite Guideline: Q8(R1) Pharmaceutical Development (http://www.ich.org/LOB/media/MEDIA4986.pdf)
International Conference of Harmonisation (2005) ICH Harmonised Tripartite Guideline: Q9 Quality Risk Management (http://www.ich.org/LOB/media/MEDIA1957.pdf)
International Conference of Harmonisation (2008) ICH Harmonised Tripartite Guideline: Q10 Pharmaceutical Quality Systems (http://www.ich.org/LOB/media/MEDIA3917.pdf)
Rathore, 2009, Quality by design for pharmaceuticals: regulatory perspective and approach, Nat. Biotechnol., 27, 26, 10.1038/nbt0109-26
Kozlowski, 2009, Considerations for biotechnology product quality by design, 9
Yu, 2004, Applications of process analytical technology to crystallization process, Adv. Drug Deliv. Rev., 56, 349, 10.1016/j.addr.2003.10.012
Rathore, 2006, Applying process analytical technology to biotech unit operations, BioPharm Int., 19, 48
Gnoth, 2007, Process analytical technology (PAT): batch-to-batch reproducibility of fermentation processes by robust process operational design and control, J. Biotechnol., 132, 180, 10.1016/j.jbiotec.2007.03.020
Harms, 2008, Defining design space for biotech products: case study of Pichia pastoris fermentation, Biotechnol. Prog., 24, 655, 10.1021/bp070338y
Rathore, 2008, Case study and application of process analytical technology (PAT) towards bioprocessing: use of on-line high performance liquid chromatography (HPLC) for making real time pooling decisions for process chromatography, Biotechnol. Bioeng., 100, 306, 10.1002/bit.21759
Nail, 2008, Elements of quality by design in development and scale-up of freeze-dried parenterals, BioPharm Int., 21, 44
van Hoek, 2009, Case study on definition of process design space for a microbial fermentation step, 85
Cecchini, 2009, Applications of design space for biopharmaceutical purification processes, 127
Watler, 2009, Application of QbD principles to tangential flow filtration operations, 111
Ng, 2009, Application of quality by design and risk assessment principles for the development of formulation design space, 161
Lanan, 2009, QbD for raw materials, 193
Department of Health and Human Services, Food and Drug Administration (2008) Notice of Pilot Program for Submission of Quality Information for Biotechnology Products in the Office of Biotechnology Products, Food and Drug Administration, Docket number FDA-2008-N-03551
Kozlowski, 2006, Current and future issues in the manufacturing and development of monoclonal antibodies, Adv. Drug Deliv. Rev., 58, 707, 10.1016/j.addr.2006.05.002
International Conference of Harmonisation (1999) ICH Harmonised Tripartite Guideline: Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products (http://www.ich.org/LOB/media/MEDIA432.pdf)
Singh, 2009, Application of QbD principles to biologic products: formulation and process development, 176
Apostol, 2008, A rational approach for setting and maintaining specifications for biological and biotechnology derived products – Part 1, BioPharm Int., 21, 42
Schofield, 2008, A rational approach for setting and maintaining specifications for biological and biotechnology derived products – Part 2, BioPharm Int., 21, 32
Schofield, 2008, A rational approach for setting and maintaining specifications for biological and biotechnology derived products – Part 3, BioPharm Int., 21, 44
Barrett, 2007, Validation and implementation of drug-dependent antibody assays in clinical trials for safety monitoring of patients dosed with roxifiban, an orally bioavailable glycoprotein IIb/IIIa antagonist, J. Pharm. Biomed. Anal., 44, 938, 10.1016/j.jpba.2007.03.030
Gupta, 2007, Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics, J. Immunol. Methods, 321, 1, 10.1016/j.jim.2006.12.004
Mire-Sluis, 2004, Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products, J. Immunol. Methods, 289, 1, 10.1016/j.jim.2004.06.002
Schenerman, 2009, Using a risk assessment process to determine criticality of product quality attributes, 53
Wang, 2007, Using statistical analysis for setting process validation acceptance criteria for biotech products, Biotech. Prog., 23, 55, 10.1021/bp060359c
Rathore, 2007, Design space for biotech products, BioPharm Int., 20, 36
Garcia, 2008, PQLI key topics – criticality, design space and control strategy, J. Pharm. Innov., 3, 60, 10.1007/s12247-008-9032-4
Seely, 2005, Process characterization, 31
Senger, 2003, Effect of shear stress on intrinsic CHO culture state and glycosylation of recombinant tissue-type plasminogen activator protein, Biotechnol. Prog., 19, 1199, 10.1021/bp025715f
Butler, 2005, Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals, Appl. Microbiol. Biotechnol., 68, 283, 10.1007/s00253-005-1980-8
Kirdar, 2008, Application of multivariate analysis for identification and resolution of a root cause for a bioprocessing application, Biotechnol. Prog., 24, 720, 10.1021/bp0704384
Rosenberg, 2006, Effects of protein aggregates: an immunologic perspective, APPS J., 8, E501
Woodcock, 2008, The FDA critical path initiative and its influence on new drug development, Annu. Rev. Med., 59, 1, 10.1146/annurev.med.59.090506.155819
Schneider, 2008, Toward biosimilar monoclonal antibodies, Nat. Biotechnol., 26, 985, 10.1038/nbt0908-985
Konold, 2009, Monitoring of biopharmaceutical processes: present and future approaches, BioPharm Int., 22, 707
Vesper, 2005, Assessing and managing risks in a GMP environment, BioPharm Int., 18, 46
Seely, 2005, Applications of failure modes and effects analysis to biotechnology manufacturing processes, 13
Shankar, 2007, A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs, Nat. Biotechnol., 25, 555, 10.1038/nbt1303
Cook, 2007, Quality by design in the CMO environment, BioPharm Int., 20, 28
Kirdar, 2007, Application of multivariate analysis towards biotech processes: case study of a cell-culture unit operation, Biotech. Prog., 23, 61, 10.1021/bp060377u
Munson, 2006, A review of process analytical technology (PAT) in the U.S. pharmaceutical industry, Curr. Pharm. Anal., 2, 405, 10.2174/157341206778699582